ArticleJournal of radiosurgery and SBRT2021
Stereotactic body radiotherapy (SBRT) for T2N0 (>3 cm) non-small cell lung cancer: Outcomes and failure patterns.
Article in Journal of radiosurgery and SBRT, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 7 citations in OpenAlex.
- The edge visualization metric: Quantifying the improvement of lung SBRT target definition with 4D CBCT.Journal of applied clinical medical physics · 2025Article
- Stereotactic radiotherapy: An educational narrative review.Precision radiation oncology · 2024Review
- Prospective study investigating hypofractionated proton beam therapy in patients with inoperable early stage non-small cell lung cancer.Frontiers in oncology · 2024Article
- Comparison of treatment planning for stereotactic radiosurgery and stereotactic body radiation therapy techniques with 2.5mm and 5mm multileaf collimator (MLC): A pilot study.F1000Research · 2024Article
- Dose-effect relationship of stereotactic body radiotherapy in non-small cell lung cancer patients.Radiation oncology (London, England) · 2022Article
- Value of carbon-ion radiotherapy for early stage non-small cell lung cancer.Clinical and translational radiation oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PURPOSE/
objectivesOutcomes of T2N0 lung cancer patients treated with stereotactic radiotherapy are not well known. METHODS AND MATERIALS: We conducted a single institution retrospective review of patients with T2N0 NSCLC who were treated with SBRT. The local, regional, distant control rates were calculated from available clinical data. Survival outcomes were determined using the Kaplan Meier method.
resultsFifty-six patients met our selection criteria. The two-year local control rate was 84.2%. The two and 5-year disease-free survival (DFS) and OS were 31.9% and 15.3% and 39.9% and 12.1%, respectively. Centroid BED
conclusionsSBRT provides good local control for T2N0 NSCLC, but systemic failure remains problematic.
Indexed as
Identifiers
34631228PMC8492054W3207767438What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.